Does separating PSA decline and regrowth improve early prediction?
A public clinical PSA dataset used to compare landmark prediction, uncertainty calibration and decline/regrowth identifiability against simple benchmarks.
Daiki Kumakura
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
Recent writing
Is another dose comparison informative? A benefit–risk analysis of ifinatamab deruxtecan
Public randomized B7-H3 ADC dose-cohort counts used to quantify conditional information value, decision uncertainty and sensitivity to unreported joint outcomes and follow-up.
What can aggregate randomized data establish about treatment duration and benefit–risk?
SCOT trial efficacy and neuropathy compared with endpoint-specific denominators, uncertainty, missingness bounds and limits of joint benefit–risk inference.